 | | Vol. 9.04 – 3 February, 2023 |
| |
|
|
| By whole-genome sequencing of 342 microdissected normal epithelial crypts from the small intestines of 39 individuals, investigators found that SBS2/SBS13 mutations were present in 17% of crypts, more frequent than most other normal tissues.
[Nature Genetics] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers showed that cell types with equivalent functional roles in the corpus and antrum shared similar transcriptional states including the poorly characterized stem cells of the isthmus region.
[Nature Cell Biology] |
|
|
|
| The authors identified a circular RNA, circBtnl1, that was highly expressed in intestinal stem cells. Loss of circBtnl1 in mice enhanced intestinal stem cell self-renewal capacity and epithelial regeneration, without changes in mRNA and protein levels of its parental gene Btnl1.
[EMBO Journal] |
|
|
|
| The apoptosis, function, and stemness of intestinal stem cells were analyzed using intestinal organoids from wild type and Fut2ΔISC mice incubated with lipopolysaccharide and fucose.
[Redox Biology] |
|
|
|
| Investigators revealed that exosomes released from imatinib-resistant gastrointestinal stromal tumors transmitted drug resistance to imatinib-sensitive tumors.
[Oncogene] |
|
|
|
| Scientists presented p73-mediated death receptor 5 induction as a potential tumor suppressive mechanism and a critical target engaged by different cyclin-dependent kinase inhibitors in potentiating therapy-induced apoptosis in colorectal cancer cells.
[Oncogene] |
|
|
|
| Investigators demonstrated that ruxolitinib alleviated colitis by inhibiting nuclear factor kappa B–related inflammation and apoptosis in addition to restoring epithelial barrier function via STAT3, providing a new strategy for ulcerative colitis treatment.
[Inflammatory Bowel Diseases] |
|
|
|
| Scientists explored the function of SNX10 in intestinal epithelial cells to provide a new target for the prevention and treatment of malignant transformation and the intervention mechanism of α-hederin for further development of potential novel agents targeting SNX10.
[Phytomedicine] |
|
|
|
|
| In patients with deficient mismatch repair and BRAFV600E metastatic colorectal cancer, randomized Phase III trials have established the efficacy of pembrolizumab as first-line therapy and the combination of encorafenib and cetuximab as second-line or third-line therapy.
[Nature Reviews Gastroenterology & Hepatology] |
|
|
|
| The authors summarize and analyze the latest knowledge to further elucidate the role of IL-22 in ulcerative colitis.
[Biomedicine & Pharmacotherapy] |
|
|
|
|
| C4 Therapeutics, Inc. announced the first patient had been dosed in its Phase I/II clinical trial of CFT1946, an orally bioavailable mutant-selective BiDACâ„¢ degrader for the treatment of BRAF V600 mutant solid tumors.
[C4 Therapeutics (Globe Newswire)] |
|
|
|
|
| February 12 – 15, 2023
Santa Fe, New Mexico, United States |
|
|
|
|
|
| | Beckman Research Institute – Monrovia, California, United States |
|
|
|
| | University of Oxford – England, United Kingdom |
|
|
|
| | Imperial College London – London, England, United Kingdom |
|
|
|
| | UT Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
| | European Molecular Biology Laboratory – Heidelberg, Germany |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
